Educational article

Rifamycins

Rifamycins act on bacterial RNA polymerase and transcription. Rifampicin is well known for its role in tuberculosis treatment, but mycobacterial standards differ from a routine antibiogram. Members of the group have…

Overview

Rifamycins act on bacterial RNA polymerase and transcription. Rifampicin is well known for its role in tuberculosis treatment, but mycobacterial standards differ from a routine antibiogram. Members of the group have different indications and pharmacokinetics.

Biology and practical meaning

rpoB changes can reduce drug binding. Molecular assays interrogate particular gene regions rather than every possible mechanism. Rifampicin resistance in tuberculosis requires specialised interpretation and further assessment under current WHO guidance.

Spectrum, exposure and AST

Spectrum describes the range of organisms an agent can act against; activity against a particular isolate is assessed separately. Access to the target, target changes, enzymes and efflux can alter activity. Agents in the same class are not completely interchangeable.

Pharmacokinetics describes distribution and elimination; pharmacodynamics links exposure to effect. Blood concentrations and exposure at the infection site can differ. A lower MIC number for a different antibiotic therefore does not establish superior clinical activity.

S, I and R are interpreted using a current standard for the organism–agent pair. Under EUCAST, I means susceptible with increased exposure. It does not mean resistant and does not independently specify a treatment regimen. Decisions also depend on the site, patient, contraindications, interactions and current guidance. This article explains mechanisms and terminology. The 2025 AWaRe classification concerns use policy, while the 2022 AWaRe book has subsequent updates; neither replaces an individual AST result.

Sources

Read next

Educational material from AMR Atlas. Does not replace clinical guidance or laboratory procedures.

Open interactive reader